YU8601A - Kristalni oblici osanetanta - Google Patents
Kristalni oblici osanetantaInfo
- Publication number
- YU8601A YU8601A YU8601A YU8601A YU8601A YU 8601 A YU8601 A YU 8601A YU 8601 A YU8601 A YU 8601A YU 8601 A YU8601 A YU 8601A YU 8601 A YU8601 A YU 8601A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- osanetant
- crystalline forms
- piperidin
- benzenesulphonate
- crystallised
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Pronalazak se odnosi na postupak za dobijanje kristalih oblika I i II od (R)-(+)-N-((3-(1-benzoil-3-(3,4-dihlorofenil) piperidin-3-il)prop-1-il)-4-fenil piperidin-4-il)-N-metil acetamida (osanetant) zajedno sa pomenutim kristalnim oblicima I i II osanetanta. Osanentant koji treba da se kristališe poželjno se dobija od benzen sulfonata.[The invention concerns a method for preparing crystalline forms I and II of (R)-(+)-N-[[3-[1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3- yl]prop-1-yl]-4-phenyl piperidin-4-yl]-N-methylacetamide (osanetant), and said crystalline forms of osanetant. Preferably, the osanetant to be crystallised is prepared from its benzenesulphonate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9810107A FR2782082B3 (fr) | 1998-08-05 | 1998-08-05 | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU8601A true YU8601A (sh) | 2003-07-07 |
Family
ID=9529458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU8601A YU8601A (sh) | 1998-08-05 | 1999-08-03 | Kristalni oblici osanetanta |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7041679B2 (sh) |
| EP (1) | EP1102747B1 (sh) |
| JP (1) | JP3807938B2 (sh) |
| KR (1) | KR100571944B1 (sh) |
| CN (1) | CN1114592C (sh) |
| AR (1) | AR019953A1 (sh) |
| AT (1) | ATE243197T1 (sh) |
| AU (1) | AU748177B2 (sh) |
| BR (1) | BR9913357A (sh) |
| CA (1) | CA2339007A1 (sh) |
| CO (1) | CO5070576A1 (sh) |
| DE (1) | DE69908951T2 (sh) |
| DK (1) | DK1102747T3 (sh) |
| DZ (1) | DZ3074A1 (sh) |
| EA (1) | EA003205B1 (sh) |
| EE (1) | EE04274B1 (sh) |
| ES (1) | ES2200535T3 (sh) |
| FR (1) | FR2782082B3 (sh) |
| HK (1) | HK1035535A1 (sh) |
| HU (1) | HUP0103134A3 (sh) |
| IS (1) | IS5821A (sh) |
| MY (1) | MY121447A (sh) |
| NO (1) | NO320645B1 (sh) |
| NZ (1) | NZ509561A (sh) |
| PL (1) | PL345999A1 (sh) |
| PT (1) | PT1102747E (sh) |
| SK (1) | SK1742001A3 (sh) |
| TR (1) | TR200100261T2 (sh) |
| TW (1) | TW527354B (sh) |
| UA (1) | UA72890C2 (sh) |
| WO (1) | WO2000007987A1 (sh) |
| YU (1) | YU8601A (sh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| US7648992B2 (en) * | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| TW200800954A (en) * | 2006-03-16 | 2008-01-01 | Astrazeneca Ab | Novel crystal modifications |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| TW202317533A (zh) * | 2021-07-02 | 2023-05-01 | 美商雅斯治療公司 | 奧沙奈坦(osanetant)之固體形式 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
| JPH1053576A (ja) * | 1996-06-07 | 1998-02-24 | Eisai Co Ltd | 塩酸ドネペジルの多形結晶およびその製造法 |
| EP0915849A2 (en) * | 1996-08-05 | 1999-05-19 | Smithkline Beecham S.p.A. | Process for the preparation of 3,3-disubstituted piperidines |
| US6040316A (en) * | 1996-09-16 | 2000-03-21 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
-
1998
- 1998-08-05 FR FR9810107A patent/FR2782082B3/fr not_active Expired - Lifetime
-
1999
- 1999-07-25 DZ DZ990156A patent/DZ3074A1/xx active
- 1999-07-28 AR ARP990103741A patent/AR019953A1/es unknown
- 1999-08-03 MY MYPI99003297A patent/MY121447A/en unknown
- 1999-08-03 EP EP99936672A patent/EP1102747B1/fr not_active Expired - Lifetime
- 1999-08-03 YU YU8601A patent/YU8601A/sh unknown
- 1999-08-03 UA UA2001010591A patent/UA72890C2/xx unknown
- 1999-08-03 WO PCT/FR1999/001914 patent/WO2000007987A1/fr not_active Application Discontinuation
- 1999-08-03 PT PT99936672T patent/PT1102747E/pt unknown
- 1999-08-03 DK DK99936672T patent/DK1102747T3/da active
- 1999-08-03 CN CN99810182A patent/CN1114592C/zh not_active Expired - Fee Related
- 1999-08-03 ES ES99936672T patent/ES2200535T3/es not_active Expired - Lifetime
- 1999-08-03 BR BR9913357-1A patent/BR9913357A/pt not_active IP Right Cessation
- 1999-08-03 KR KR1020017001460A patent/KR100571944B1/ko not_active IP Right Cessation
- 1999-08-03 EE EEP200100070A patent/EE04274B1/xx not_active IP Right Cessation
- 1999-08-03 PL PL99345999A patent/PL345999A1/xx not_active Application Discontinuation
- 1999-08-03 AT AT99936672T patent/ATE243197T1/de not_active IP Right Cessation
- 1999-08-03 DE DE69908951T patent/DE69908951T2/de not_active Expired - Fee Related
- 1999-08-03 JP JP2000563621A patent/JP3807938B2/ja not_active Expired - Fee Related
- 1999-08-03 HU HU0103134A patent/HUP0103134A3/hu unknown
- 1999-08-03 NZ NZ509561A patent/NZ509561A/xx unknown
- 1999-08-03 EA EA200100096A patent/EA003205B1/ru not_active IP Right Cessation
- 1999-08-03 CA CA002339007A patent/CA2339007A1/en not_active Abandoned
- 1999-08-03 SK SK174-2001A patent/SK1742001A3/sk unknown
- 1999-08-03 TR TR2001/00261T patent/TR200100261T2/xx unknown
- 1999-08-03 AU AU51685/99A patent/AU748177B2/en not_active Ceased
- 1999-08-04 TW TW088113235A patent/TW527354B/zh not_active IP Right Cessation
- 1999-08-04 CO CO99049286A patent/CO5070576A1/es unknown
-
2001
- 2001-01-23 IS IS5821A patent/IS5821A/is unknown
- 2001-02-01 NO NO20010553A patent/NO320645B1/no unknown
- 2001-09-04 HK HK01106232A patent/HK1035535A1/xx not_active IP Right Cessation
-
2003
- 2003-08-28 US US10/651,313 patent/US7041679B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU8601A (sh) | Kristalni oblici osanetanta | |
| HUP9904125A3 (en) | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists | |
| HU9601634D0 (en) | Morpholine and thiomorpholine tachykinin receptor antagonists | |
| CA2200356A1 (en) | Process for preparing levobupivacaine and analogues thereof | |
| NZ334017A (en) | 1,4-di-substituted piperidines and use in combination with acetylcholinesterase inhibitors for treating cognitive disorders | |
| NO20043341L (no) | Fremgangsmate for fremstilling av scopinestere | |
| IL117446A0 (en) | Esters and amides of disubstituted 1,4-piperidine | |
| HUT63384A (en) | Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds | |
| CA2258701A1 (en) | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | |
| IL136421A0 (en) | Intermediates for preparing 1-benzyl -4-((5,6- dimethoxy -1-indanon)-2-yl) methylpiperidine | |
| EP0923553A4 (en) | STABLE, NON-HYGROSCOPIC, CRYSTALLINE FORM OF N-ÄN-N (4- (PIPERIDIN-4-YL) BUTANOYL) -N-ETHYLGLYCYL COMPOUNDS | |
| PL327440A1 (en) | N-acyl-substituted 4-(benzimidazollyl- or imidarolylpyrimidyl-substituted) piperidines as antagonists of tachykinin | |
| ZA971735B (en) | Novel esters of 1,4-disubstituted piperidine derivatives | |
| HK1035001A1 (en) | Method for enzymatic enantiomer-separation of 3(R)-and 3(s)-hydroxy-1-methyl-4-(2,4,6-trimethoxyphe nyl)-1,2,3,6-tetrahydro-pyridine or its carboxylicacid esters | |
| TR199701362T1 (xx) | Ropivakain hidroklor�r monohidrat�n haz�rlanmas�nda yeni i�lem. | |
| EP0714890A3 (de) | Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin | |
| MX9708612A (es) | Derivados de alfa-(alquilfenilo sustituido)-4-(hidroxidifenilmetil)-1-piperidinbutanol, su preparacion y su uso como antihistaminas, agentes antialergicos, y broncodilatadores. | |
| EE200000290A (et) | Toimeainete, nimelt tetrahüdropüridiinide ja atsetüülkoliinesteraasi inhibiitorite, kombinatsioon Alzheimeri tõve tüüpi seniildementsuse raviks | |
| HU912469D0 (en) | Process for producing piperidine derivatives acting as inhibitor during synthesis of cholesterol | |
| MY118015A (en) | Method of crystallizing a tetrahydropyridine derivative and crystalline forms thereby obtained | |
| PL340544A1 (en) | Substituted oximes as antagonists of neurokinin | |
| MY126298A (en) | Microparticulate form of a tetrahydropyridine derivative | |
| RU99115083A (ru) | 1-фенилалкил-1,2,3,6-тетрагидропиридины для лечения болезни альцгеймера | |
| DK0950052T3 (da) | Fremgangsmåde til fremstilling af et tetrahydropyridin-derivat | |
| IL154302A0 (en) | Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine |